m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05650
 [1]
m6A modification Circ_IRF2 Circ_IRF2 YTHDF2 : m6A sites Direct Inhibition Non-coding RNA circIRF2 miR-29b-1-5p  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
m6A Target Circ_IRF2
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_IRF2 circRNA View Details
Regulated Target hsa-miR-29b-1-5p View Details
Crosstalk Relationship m6A  →  ncRNA Inhibition
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary YTHDF2 recognized m6A-modified Circ_IRF2 and diminished circIRF2 stability, partly accounting for the decreased circIRF2 in liver fibrosis. Cytoplasmic circIRF2 may directly harbor hsa-miR-29b-1-5p and competitively relieve its inhibitory effect on FOXO3, inducing FOXO3 nuclear translocation and accumulation.
Responsed Disease Hepatic fibrosis/cirrhosis ICD-11: DB93
 Disease Info 
Cell Process mRNA stability
In-vitro Model
LX-2
 N.A. Homo sapiens CVCL_5792
In-vivo Model for the TAA (Sigma-Aldrich, USA) induced mouse liver fibrosis model, briefly, TAA (200 mg/kg, diluted in saline) was injected 3 times weekly for 8 weeks. Mice were sacrificed 24 h after the last administration.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
DB93: Hepatic fibrosis/cirrhosis 5 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name KB174 Clinical Trial [2]
External Link
TTD: DDNL40
 Compound Name Quinazoline derivative 12 Patented [3]
Synonyms
PMID26936077-Compound-23
    Click to Show/Hide
External Link
CID: 60163336
TTD: D0EC3H
 Compound Name Quinazoline derivative 10 Patented [3]
Synonyms
PMID26936077-Compound-21
    Click to Show/Hide
External Link
CID: 6737869
TTD: D0CM5P
 Compound Name Quinazoline derivative 11 Patented [3]
Synonyms
PMID26936077-Compound-22
    Click to Show/Hide
External Link
CID: 60163203
TTD: D08ZEM
 Compound Name PMID27998201-Compound-5 Patented [4]
External Link
CID: 46202117
TTD: D05OIU
References
Ref 1 N(6)-methyladenosine-modified circIRF2, identified by YTHDF2, suppresses liver fibrosis via facilitating FOXO3 nuclear translocation. Int J Biol Macromol. 2023 Sep 1;248:125811. doi: 10.1016/j.ijbiomac.2023.125811. Epub 2023 Jul 17.
Ref 2 ClinicalTrials.gov (NCT03855956) Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis. U.S. National Institutes of Health.
Ref 3 Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.
Ref 4 Cathepsin B and L inhibitors: a patent review (2010 - present). Expert Opin Ther Pat. 2017 Jun;27(6):643-656. doi: 10.1080/13543776.2017.1272572. Epub 2016 Dec 23.